Related Experiment Video

Updated: Jul 13, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Three different bradycardic agents, zatebradine, diltiazem and propranolol, distinctly modify heart rate variability

Motoko Yamabe1, Shamarendra N Sanyal, Shinji Miyamoto

  • 1Department of Cardiovascular Science, Oita University School of Medicine, Oita, Japan.

Pharmacology
|August 11, 2007
PubMed

Insights

Different antiarrhythmic drugs affect heart rate variability and QT-interval variability uniquely. Zatebradine showed no effect, while diltiazem and propranolol altered HRV and QTV, impacting clinical understanding of their actions.

Area of Science:

  • Pharmacology
  • Cardiology
  • Computational Biology

Background:

  • Zatebradine, diltiazem, and propranolol are antiarrhythmic agents inducing bradycardia via distinct molecular mechanisms.
  • Zatebradine blocks the hyperpolarization-activated inward current (I(f)), diltiazem blocks L-type Ca(2+) channels (I(CaL)), and propranolol is a beta-blocker.

Purpose of the Study:

  • To investigate the distinct effects of zatebradine, diltiazem, and propranolol on heart rate variability (HRV) and QT-interval variability (QTV).
  • To elucidate the underlying mechanisms of their clinical antiarrhythmic and/or proarrhythmic actions.

Main Methods:

  • Guinea pigs were administered zatebradine, diltiazem, or propranolol at doses reducing heart rate by 20-22%.
  • Heart rate variability and QT-interval variability were analyzed using fast Fourier and/or wavelet transform algorithms.

Main Results:

  • Zatebradine (I(f) channel blocker) had no significant effect on HRV or QTV.
  • Diltiazem (I(CaL) blocker) increased high-frequency HRV power, decreased the LF/HF ratio, and increased QTV.
  • Propranolol (beta-blocker) decreased low-frequency HRV power and the LF/HF ratio, and reduced QTV.

Conclusions:

  • The distinct effects of these agents on HRV and QTV highlight their differing pharmacological actions.
  • Understanding these variations is crucial for predicting and managing the clinical antiarrhythmic and proarrhythmic potential of these heart rate-lowering drugs.

More Related Videos

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...